Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

LIFEOMEGA

Financiado

Cerrado

Innovative highly concentrated Omega 3 food supplement

The project aims to develop an innovative food supplement consisting on a high concentrated emulsion of Omega-3 fatty acid EPA. Omega-3 is utilized as a treatment in psoriasis, arthritis, asthma, multiple sclerosis, chronic inflam... ver más

31/12/2015

SOLUCIONES EXTRACT...

71K€

Presupuesto del proyecto: 71K€

Líder del proyecto

SOLUCIONES EXTRACTIVAS ALIMENTARIAS La investigación, desarrollo, producción, comercialización y compra venta de productos químicos, biológicos e ingredientes para la industria...

TRL 4-5 | 1M€

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2015-12-31

SFS-08-2015-1: Resource-efficient eco-innovative f...

I+D

Cerrada hace 9 años

0% 70% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

SOLUCIONES EXTRACTIVAS ALIME...

50.00K€ | Lider

Proyectos interesantes

LIFEOMEGA

Medical Technol...

Nutrition

2M€ Cerrado

AGL2013-49079-C2-2-R

Medical Technol...

Nutrition Scien...

266K€ Cerrado

MicroPUFA

Medical Technol...

Biotechnology

255K€ Cerrado

RTC-2017-5853-1

Medical Technol...

Food Technology

353K€ Cerrado

CTQ2017-87076-R

Medical Technol...

Food Technology

151K€ Cerrado

PTQ-08-01-06446

Medical Technol...

Nanotechnology

100K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 6 meses Fecha Inicio: 2015-06-16
Fecha Fin: 2015-12-31

Líder del proyecto

SOLUCIONES EXTRACTIVAS ALIMENTARIAS La investigación, desarrollo, producción, comercialización y compra venta de productos químicos, biológicos e ingredientes para la industria...

TRL 4-5 | 1M€

Presupuesto del proyecto 71K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The project aims to develop an innovative food supplement consisting on a high concentrated emulsion of Omega-3 fatty acid EPA. Omega-3 is utilized as a treatment in psoriasis, arthritis, asthma, multiple sclerosis, chronic inflammatory, cancer, high TGs, retinal diseases and cardiovascular failure. It consists of 15 ml liquid concentration of EPA, minimizing the level of saturated fats. It’s high concentrated -3 grams EPA/ sachet–, so it allows meeting the nutritional requirements in fewer dosages. Similar products in the market are constituted of maximum 1 gr. EPA, in which a higher concentration means higher level of saturated fats. Liquid form permits the dilution in other liquids, as milk, soup, or juice. These features permit the following applications: 1) Clinical nutrition: most of cancer patients suffer cachexia or anorexia. EPA supports weight management, reduce the pro-inflammatory response and improve quality of life. 2) Dietary supplement: EPA helps maintaining the musculature and protecting the joints, so it is ideal for competition athletes. Innovation is present in all aspects: application, as the multiple emulsions technology is applied to food products – normally it is applied in cosmetic or pharma-; product, as there are no products in the market offering such a high EPA concentration in liquid form minimizing the saturated fats; design, as it has liquid form; and solution, as the mentioned features constitute a solution for people having an extra requirement of fatty acids. Goal in phase I is to develop a feasibility study, including a business plan which will cover all aspects of commercialization of LIFEOMEGA: technical, economical, risk assessment, IP, regulatory, bottle necks, market study, partner search, among others. LIFEOMEGA has a great potential, as it is estimated that cancer patients receiving chemotherapy unfortunately won’t be less than 1 million/year during the next 11 years, in USA, Spain, France, Germany, UK and Italy.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores